Genomics and drug discovery.
Genomics, the systematic study of all the genes of an organism, offers a new and much-needed source of systematic productivity for the pharmaceutical industry. The isolation of the majority of human genes in their most useful form is leading to the creation of new drugs based on human proteins, antibodies, peptides, and genes. Human Genome Sciences, Inc, was the first company to use the systematic, genomics approach to discovering drugs, and we have placed 4 of these in clinical trials. Two are described: repifermin (keratinocyte growth factor-2, KGF-2) for wound healing and treatment of mucositis caused by cancer therapy, and B lymphocyte stimulator (BLyS) for stimulation of the immune system. An anti-BLyS antibody drug is in advanced preclinical development for treatment of autoimmune diseases.
Haseltine
W A
WA
Human Genome Sciences, Inc., 9410 Key West Ave., Rockville, MD 20850-3338, USA.
D002986:Clinical Trials as Topic; D017277:Drug Approval; D015894:Genome, Human; D023281:Genomics; D006801:Humans